SH2 domain binding to phosphopeptide ligands: Potential for drug targeting

Frontiers in Bioscience

Volumn 14, Issue 3, 2009, Pages 1010-1022

  Kasembeli, Moses M ^a   Xu, Xuejun ^a   Tweardy, David J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Binding; Motif; Phophopeptide; Review; SH2; Specificity; STAT

Indexed keywords

MAMMALIA;

LIGAND; PHOSPHOPEPTIDE; STAT PROTEIN;

DRUG DELIVERY SYSTEM; METABOLISM; PROTEIN BINDING; REVIEW; SRC HOMOLOGY DOMAIN;

DRUG DELIVERY SYSTEMS; LIGANDS; PHOSPHOPEPTIDES; PROTEIN BINDING; SRC HOMOLOGY DOMAINS; STAT TRANSCRIPTION FACTORS;

EID: 63849341033     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3292     Document Type: Article

References (90)

1. Sadowski, I., J. C. Stone & T. Pawson: A Noncatalytic Domain Conserved among Cytoplasmic Protein-Tyrosine Kinases Modifies the Kinase Function and Transforming Activity of Fujinami Sarcoma-Virus P130gag-Fps. Molecular and Cellular Biology, 6, 4396- 4408 (1986). (Pubitemid 17217381)
2. Koch, C. A., D. Anderson, M. F. Moran, C. Ellis & T. Pawson: Sh2 and Sh3 Domains - Elements That Control Interactions of Cytoplasmic Signaling Proteins. Science, 252, 668-674 (1991). (Pubitemid 21916987)
3. Pawson, T., G. D. Gish & P. Nash: SH2 domains, interaction modules and cellular wiring. Trends in Cell Biology, 11, 504-511 (2001). (Pubitemid 33079144)
4. Hirai, H. & H. E. Varmus: Site-Directed Mutagenesis of the Sh2-Coding and Sh3-Coding Domains of C-Src Produces Varied Phenotypes, Including Oncogenic Activation of P60c-Src. Molecular and Cellular Biology, 10, 1307-1318 (1990).
5. Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. X. Zhao, R. G. Pestell, C. Albanese & J. E. Darnell: Stat3 as an oncogene. Cell, 98, 295-303 (1999). (Pubitemid 29380565)
6. Schwartzberg, P. L., L. P. Xing, O. Hoffmann, C. A. Lowell, L. Garrett, B. F. Boyce & H. E. Varmus: Rescue of osteoclast function by transgenic expression of kinasedeficient Src in src-/- mutant mice. Genes & Development, 11, 2835-2844 (1997). (Pubitemid 27481684)
7. Miled, N., Y. Yan, W. C. Hon, O. Perisic, M. Zvelebil, Y. Inbar, D. Schneidman-Duhovny, H. J. Wolfson, J. M. Backer & R. L. Williams: Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science, 317, 239-242 (2007). (Pubitemid 47076198)
8. Yu, H. & R. Jove: The stats of cancer - New molecular targets come of age. Nature Reviews Cancer, 4, 97-105 (2004). (Pubitemid 38198738)
9. Redell, M. S. & D. J. Tweardy: Targeting transcription factors for cancer therapy. Current Pharmaceutical Design, 11, 2873-2887 (2005). (Pubitemid 41051872)
10. Anderson, D., C. A. Koch, L. Grey, C. Ellis, M. F. Moran & T. Pawson: Binding of Sh2 Domains of Phospholipase-C-Gamma-1, Gap, and Src to Activated Growth-Factor Receptors. Science, 250, 979-982 (1990). (Pubitemid 120031802)
11. Kuriyan, J. & D. Cowburn: Modular peptide recognition domains in eukaryotic signaling. Annual Review of Biophysics and Biomolecular Structure, 26, 259- 288 (1997). (Pubitemid 27255374)
12. Waksman, G., D. Kominos, S. C. Robertson, N. Pant, D. Baltimore, R. B. Birge, D. Cowburn, H. Hanafusa, B. J. Mayer, M. Overduin, M. D. Resh, C. B. Rios, L. Silverman & J. Kuriyan: Crystal-Structure of the Phosphotyrosine Recognition Domain Sh2 of V-Src Complexed with Tyrosine- Phosphorylated Peptides. Nature, 358, 646-653 (1992).
13. Booker, G. W., A. L. Breeze, A. K. Downing, G. Panayotou, I. Gout, M. D. Waterfield & I. D. Campbell: Structure of an Sh2 Domain of the P85-Alpha Subunit of Phosphatidylinositol-3-Oh Kinase. Nature, 358, 684-687 (1992).
14. Eck, M. J., S. E. Shoelson & S. C. Harrison: Recognition of a High-Affinity Phosphotyrosyl Peptide by the Src Homology-2 Domain of P56 (Lck). Nature, 362, 87-91 (1993). (Pubitemid 23087298)
15. Waksman, G., S. E. Shoelson, N. Pant, D. Cowburn & J. Kuriyan: Binding of a High-Affinity Phosphotyrosyl Peptide to the Src Sh2 Domain - Crystal-Structures of the Complexed and Peptide-Free Forms. Cell, 72, 779-790 (1993). (Pubitemid 23093885)
16. Rahuel, J., B. Gay, D. Erdmann, A. Strauss, C. GarciaEcheverria, P. Furet, G. Caravatti, H. Fretz, J. Schoepfer & M. G. Grutter: Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode. Nature Structural Biology, 3, 586-589 (1996).
17. Nioche, P., W. Q. Liu, I. Broutin, F. Charbonnier, M. T. Latreille, M. Vidal, B. Roques, C. Garbay & A. Ducruix: Crystal structures of the SH2 domain of Grb2: Highlight on the binding of a new high-affinity inhibitor. Journal of Molecular Biology, 315, 1167-1177 (2002). (Pubitemid 34729294)
18. Thornton, K. H., W. T. Mueller, P. McConnell, G. C. Zhu, A. R. Saltiel & V. Thanabal: Nuclear magnetic resonance solution structure of the growth factor receptorbound protein 2 Src homology 2 domain. Biochemistry, 35, 11852-11864 (1996). (Pubitemid 26303705)
19. Maignan, S., J. P. Guilloteau, N. Fromage, B. Arnoux, J. Becquart & A. Ducruix: Crystal-Structure of the Mammalian Grb2 Adapter. Science, 268, 291-293 (1995).
20. Ogura, K., S. Tsuchiya, H. Terasawa, S. Yuzawa, H. Hatanaka, V. Mandiyan, J. Schlessinger & F. Inagaki: Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide. Journal of Molecular Biology, 289, 439-445 (1999). (Pubitemid 29295115)
21. Marengere, L. E. M., S. Y. Zhou, G. D. Gish, M. D. Schaller, J. T. Parsons, M. J. Stern, L. C. Cantley & T. Pawson: Sh2 Domain Specificity and Activity Modified by a Single Residue. Nature, 369, 502-505 (1994). (Pubitemid 24210572)
22. Kimber, M. S., J. Nachman, A. M. Cunningham, G. D. Gish, T. Pawson & E. F. Pai: Structural basis for specificity switching of the Src SH2 domain. Molecular Cell, 5, 1043-1049 (2000).
23. Frese, S., W. D. Schubert, A. C. Findeis, T. Marquardt, Y. S. Roske, T. E. B. Stradal & D. W. Heinz: The phosphotyrosine peptide binding specificity of Nck1 and Nck2 Src homology 2 domains. Journal of Biological Chemistry, 281, 18236-18245 (2006). (Pubitemid 44035624)
24. Xu, R. X., J. M. Word, D. G. Davis, M. J. Rink, D. H. Willard & R. T. Gampe: Solution Structure of the Human Pp60 (C-Src) Sh2 Domain Complexed with a Phosphorylated Tyrosine Pentapeptide. Biochemistry, 34, 2107-2121 (1995).
25. Pascal, S. M., A. U. Singer, G. Gish, T. Yamazaki, S. E. Shoelson, T. Pawson, L. E. Kay & J. D. Formankay: Nuclear-Magnetic-Resonance Structure of an Sh2 Domain of Phospholipase C-Gamma-1 Complexed with a High-Affinity Binding Peptide. Cell, 77, 461-472 (1994).
26. Bradshaw, J. M., V. Mitaxov & G. Waksman: Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase. Journal of Molecular Biology, 293, 971-985 (1999). (Pubitemid 29527677)
27. Mayer, B. J., P. K. Jackson, R. A. Vanetten & D. Baltimore: Point Mutations in the Abl Sh2 Domain Coordinately Impair Phosphotyrosine Binding Invitro and Transforming Activity Invivo. Molecular and Cellular Biology, 12, 609-618 (1992).
28. Chen, X. M., U. Vinkemeier, Y. X. Zhao, D. Jeruzalmi, J. E. Darnell & J. Kuriyan: Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell, 93, 827- 839 (1998). (Pubitemid 28257588)
29. Mao, X., Z. Y. Ren, G. N. Parker, H. Sondermann, M. A. Pastorello, W. Wang, J. S. McMurray, B. Demeler, J. E. Darnell & X. M. Chen: Structural bases of unphosphorylated STAT1 association and receptor binding. Molecular Cell, 17, 761-771 (2005). (Pubitemid 40386938)
30. Lemmon, M. A. & J. E. Ladbury: Thermodynamic Studies of Tyrosyl-Phosphopeptide Binding to the Sh2 Domain of P56 (Lck). Biochemistry, 33, 5070-5076 (1994). (Pubitemid 24150972)
31. Ladbury, J. E., M. A. Lemmon, M. Zhou, J. Green, M. C. Botfield & J. Schlessinger: Measurement of the Binding of Tyrosyl Phosphopeptides to Sh2 Domains - a Reappraisal. Proceedings of the National Academy of Sciences of the United States of America, 92, 3199-3203 (1995).
32. Bradshaw, J. M., R. A. Grucza & G. Waksman: Binding thermodynamics of protein modules involved in tyrosine kinase signaling pathways In: The thermodynamics of the drug-receptor interaction. In: Drug-Receptor thermodynamics: Introduction and Application. Ed: R. B. Raffa. John Wiley & sons. Ltd., (2000).
33. Grucza, R. A., J. M. Bradshaw, K. Futterer & G. Waksman: SH2 domains: From structure to energetics, a dual approach to the study of structure-function relationships. Medicinal Research Reviews, 19, 273-293 (1999). (Pubitemid 29319232)
34. Bibbins, K. B., H. Boeuf & H. E. Varmus: Binding of the Src Sh2 Domain to Phosphopeptides Is Determined by Residues in Both the Sh2 Domain and the Phosphopeptides. Molecular and Cellular Biology, 13, 7278-7287 (1993). (Pubitemid 23354251)
35. Roussel, R. R., S. R. Brodeur, D. Shalloway & A. P. Laudano: Selective Binding of Activated Pp60c-Src by an Immobilized Synthetic Phosphopeptide Modeled on the Carboxyl Terminus of Pp60c-Src. Proceedings of the National Academy of Sciences of the United States of America, 88, 10696-10700 (1991). (Pubitemid 21915904)
36. McNemar, C., M. E. Snow, W. T. Windsor, A. Prongay, P. Mui, R. M. Zhang, J. Durkin, H. V. Le & P. C. Weber: Thermodynamic and structural analysis of phosphotyrosine polypeptide binding to Grb2-SH2. Biochemistry, 36, 10006-10014 (1997). (Pubitemid 27357708)
37. Bradshaw, J. M., R. A. Grucza, J. E. Ladbury & G. Waksman: Probing the "two-pronged plug two-holed socket" model for the mechanism of binding of the Src SH2 domain to phosphotyrosyl peptides: A thermodynamic study. Biochemistry, 37, 9083-9090 (1998). (Pubitemid 28299681)
38. Bradshaw, J. M. & G. Waksman: Calorimetric examination of high-affinity Src SH2 domain-tyrosyl phosphopeptide binding: Dissection of the phosphopeptide sequence specificity and coupling energetics. Biochemistry, 38, 5147-5154 (1999).
39. Wiederkehr-Adam, M., P. Ernst, K. Muller, E. Bieck, F. O. Gombert, J. Ottl, P. Graff, F. Grossmuller & M. H. Heim: Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. Journal of Biological Chemistry, 278, 16117-16128 (2003). (Pubitemid 36799733)
40. Henriques, D. A. & J. E. Ladbury: Inhibitors to the Src SH2 domain: A lesson in structure-thermodynamic correlation in drug design. Archives of Biochemistry and Biophysics, 390, 158-168 (2001). (Pubitemid 32568477)
41. Lubman, O. Y. & G. Waksman: Structural and thermodynamic basis for the interaction of the Src SH2 domain with the activated form of the PDGF beta-receptor. Journal of Molecular Biology, 328, 655-668 (2003). (Pubitemid 36438579)
42. Zhou, S. Y., S. E. Shoelson, M. Chaudhuri, G. Gish, T. Pawson, W. G. Haser, F. King, T. Roberts, S. Ratnofsky, R. J. Lechleider, B. G. Neel, R. B. Birge, J. E. Fajardo, M. M. Chou, H. Hanafusa, B. Schaffhausen & L. C. Cantley: Sh2 Domains Recognize Specific Phosphopeptide Sequences. Cell, 72, 767-778 (1993). (Pubitemid 23093884)
43. Songyang, Z., S. E. Shoelson, J. McGlade, P. Olivier, T. Pawson, X. R. Bustelo, M. Barbacid, H. Sabe, H. Hanafusa, T. Yi, R. Ren, D. Baltimore, S. Ratnofsky, R. A. Feldman & L. C. Cantley: Specific Motifs Recognized by the Sh2 Domains of Csk, 3bp2, Fps Fes, Grb-2, Hcp, Shc, Syk, and Vav. Molecular and Cellular Biology, 14, 2777-2785 (1994).
44. Soler-Lopez, M., C. Petosa, M. Fukuzawa, R. Ravelli, J. G. Williams & C. W. Muller: Structure of an activated Dictyostelium STAT in its DNA-unbound form. Molecular Cell, 13, 791-804 (2004). (Pubitemid 38438475)
45. Chakraborty, A., K. F. Dyer, M. Cascio, T. A. Mietzner & D. J. Tweardy: Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood, 93, 15-24 (1999). (Pubitemid 29019383)
46. Shao, H., X. J. Xu, N. J. Jing & D. J. Tweardy: Unique structural determinants for Stat3 recruitment and activation by the granulocyte colony-stimulating factor receptor at phosphotyrosine Ligands 704 and 744. Journal of Immunology, 176, 2933-2941 (2006).
47. Shao, H., X. J. Xu, M. A. A. Mastrangelo, N. J. Jing, R. G. Cook, G. B. Legge & D. J. Tweardy: Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. Journal of Biological Chemistry, 279, 18967-18973 (2004). (Pubitemid 38623326)
48. Sheinerman, F. B., B. Al-Lazikani & B. Honig: Sequence, structure and energetic determinants of phosphopeptide selectivity of SH2 domains. Journal of Molecular Biology, 334, 823-841 (2003). (Pubitemid 37433895)
49. Cowan-Jacob, S. W., G. Fendrich, P. W. Manley, W. Jahnke, D. Fabbro, J. Liebetanz & T. Meyer: The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure, 13, 861-871 (2005). (Pubitemid 40804389)
50. Sicheri, F., I. Moarefi & J. Kuriyan: Crystal structure of the Src family tyrosine kinase Hck. Nature, 385, 602-609 (1997). (Pubitemid 27087567)
51. Hu, J. J. & S. R. Hubbard: Structural basis for phosphotyrosine recognition by the Src homology-2 domains of the adapter proteins SH2-B and APS. Journal of Molecular Biology, 361, 69-79 (2006). (Pubitemid 44041451)
52. Darnell, J. E.: STATs and gene regulation. Science, 277, 1630-1635 (1997).
53. Leonard, W. J. & J. J. O'Shea: JAKS AND STATS: Biological implications. Annual Review of Immunology, 16, 293-322 (1998). (Pubitemid 28183367)
54. Yu, C. L., D. J. Meyer, G. S. Campbell, A. C. Larner, C. Cartersu, J. Schwartz & R. Jove: Enhanced DNABinding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein. Science, 269, 81- 83 (1995).
55. Barton, B. E.: STAT3: A molecular target for cancer whose time has come. Current Signal Transduction Therapy, 1, 239-253 (2006).
56. Haura, E. B., Z. Zheng, L. X. Song, A. Cantor & G. Bepler: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clinical Cancer Research, 11, 8288-8294 (2005). (Pubitemid 41746939)
57. Buettner, R., L. B. Mora & R. Jove: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical Cancer Research, 8, 945-954 (2002). (Pubitemid 35177340)
58. Turkson, J. & R. Jove: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 19, 6613- 6626 (2000). (Pubitemid 32197700)
59. Garcia, R. & R. Jove: Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. Journal of Biomedical Science, 5, 79-85 (1998). (Pubitemid 28253097)
60. Gao, Q., J. Hua, R. Kimura, J. J. Headd, X. Y. Fu & Y. E. Chin: Identification of the linker-SH2 domain of STAT as the origin of the SH2 domain using two-dimensional structural alignment. Molecular & Cellular Proteomics, 3, 704-714 (2004). (Pubitemid 39077001)
61. Kawata, T., A. Shevchenko, M. Fukuzawa, K. A. Jermyn, N. F. Totty, N. V. Zhukovskaya, A. E. Sterling, M. Mann & J. G. Williams: SH2 signaling in a lower eukaryote: A STAT protein that regulates stalk cell differentiation in Dictyostelium. Cell, 89, 909-916 (1997). (Pubitemid 27513517)
62. Fukuzawa, M., T. Araki, I. Adrian & J. G. Williams: Tyrosine phosphorylation-independent nuclear translocation of a Dictyostelium STAT in response to DIF signaling. Molecular Cell, 7, 779-788 (2001). (Pubitemid 32436438)
63. Kuriyan, G. W. a. J.: Structure and Specificity of the SH2 Domain. Cell, 116, S45-S51 (2004).
64. Greenlund, A. C., M. O. Morales, B. L. Viviano, H. Yan, J. Krolewski & R. D. Schreiber: Stat Recruitment by Tyrosine-Phosphorylated Cytokine Receptors - an Ordered Reversible Affinity-Driven Process. Immunity, 2, 677-687 (1995).
65. Tweardy, D. J., T. M. Wright, S. F. Ziegler, H. Baurmann, A. Chakraborty, S. M. White, K. F. Dyer & K. A. Rubin: Granulocyte-Colony-Stimulating Factor Rapidly Activates a Distinct Stat-Like Protein in Normal Myeloid Cells. Blood, 86, 4409-4416 (1995).
66. Tian, S. S., P. Lamb, H. M. Seidel, R. B. Stein & J. Rosen: Rapid Activation of the Stat3 Transcription Factor by Granulocyte-Colony-Stimulating Factor. Blood, 84, 1760-1764 (1994).
67. Becker, S., B. Groner & C. W. Muller: Three-dimensional structure of the Stat3 beta homodimer bound to DNA. Nature, 394, 145-151 (1998). (Pubitemid 28325960)
68. Azam, M., H. Erdjument-bromage, B. L. Kreider, M. Xia, F. Quelle, R. Basu, C. Saris, P. Tempst, J. N. Ihle & C. Schindler: Interleukin-3 Signals through Multiple Isoforms of Stat5. Embo Journal, 14, 1402-1411 (1995).
69. Kung, C. K. H., T. Miyake & E. Goldwasser: Purification of Human Erythropoietin. Federation Proceedings, 36, 895- 895 (1977).
70. Quelle, F. W., D. Wang, T. Nosaka, W. E. Thierfelder, D. Stravopodis, Y. Weinstein & J. N. Ihle: Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Molecular and Cellular Biology, 16, 1622-1631 (1996). (Pubitemid 26095634)
71. May, P., C. Gerhartz, B. Heesel, T. Welte, W. Doppler, L. Graeve, F. Horn & P. C. Heinrich: Comparative study on the phosphotyrosine motifs of different cytokine receptors involved in STAT5 activation. Febs Letters, 394, 221-226 (1996). (Pubitemid 26341510)
72. Bowman, T., R. Garcia, J. Turkson & R. Jove: STATs in oncogenesis. Oncogene, 19, 2474-2488 (2000). (Pubitemid 30339203)
73. Li, L. & P. E. Shaw: Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. Journal of Biological Chemistry, 277, 17397- 17405 (2002). (Pubitemid 34967539)
74. Grandis, J. R., S. D. Drenning, Q. Zeng, S. C. Watkins, M. F. Melhem, S. Endo, D. E. Johnson, L. Huang, Y. K. He & J. D. Kim: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 97, 4227-4232 (2000). (Pubitemid 30226115)
75. Epling-Burnette, P. K., J. H. Liu, R. Catlett-Falcone, J. Turkson, M. Oshiro, R. Kothapalli, Y. X. Li, J. M. Wang, H. F. Yang-Yen, J. Karras, R. Jove & T. P. Loughran: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. Journal of Clinical Investigation, 107, 351-361 (2001). (Pubitemid 32157967)
76. Leong, P. L., G. A. Andrews, D. E. Johnson, K. F. Dyer, S. C. Xi, J. C. Mai, P. D. Robbins, S. Gadiparthi, N. A. Burke, S. F. Watkins & J. R. Grandis: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proceedings of the National Academy of Sciences of the United States of America, 100, 4138-4143 (2003). (Pubitemid 36418170)
77. Niu, G. L., K. L. Wright, M. Huang, L. X. Song, E. Haura, J. Turkson, S. M. Zhang, T. H. Wang, D. Sinibaldi, D. Coppola, R. Heller, L. M. Ellis, J. Karras, J. Bromberg, D. Pardoll, R. Jove & H. Yu: Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene, 21, 2000-2008 (2002). (Pubitemid 34270888)
78. Turkson, J., J. S. Kim, S. M. Zhang, J. Yuan, M. Huang, M. Glenn, E. Haura, S. Sebti, A. D. Hamilton & R. Jove: Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Molecular Cancer Therapeutics, 3, 261-269 (2004). (Pubitemid 39193701)
79. Coleman, D. R., Z. Y. Ren, P. K. Mandal, A. G. Cameron, G. A. Dyer, S. Muranjan, M. Campbell, X. M. Chen & J. S. McMurray: Investigation of the binding determinants of phosphopeptides targeted to the Src homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. Journal of Medicinal Chemistry, 48, 6661-6670 (2005). (Pubitemid 41504722)
80. Turkson, J., D. Ryan, J. S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laudano, S. Sebti, A. D. Hamilton & R. Jove: Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. Journal of Biological Chemistry, 276, 45443-45455 (2001).
81. Jing, N. J., Y. D. Li, W. J. Xiong, W. Sha, L. Jing & D. J. Tweardy: G-quartet oligonucleotides: A new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Research, 64, 6603-6609 (2004). (Pubitemid 39297920)
82. Siddiquee, K., S. Zhang, W. C. Guida, M. A. Blaskovich, B. Greedy, H. R. Lawrence, M. L. R. Yip, R. Jove, M. M. McLaughlin, N. J. Lawrence, S. M. Sebti & J. Turkson: Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences of the United States of America, 104, 7391-7396 (2007). (Pubitemid 47185916)
83. Schust, J., B. Sperl, A. Hollis, T. U. Mayer & T. Berg: Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chemistry & Biology, 13, 1235-1242 (2006). (Pubitemid 44750735)
84. Song, H., R. X. Wang, S. M. Wang & J. Lin: A low-molecular- weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 102, 4700-4705 (2005). (Pubitemid 40471517)
85. Yan, H., K. Krishnan, A. C. Greenlund, S. Gupta, J. T. E. Lim, R. D. Schreiber, C. W. Schindler & J. J. Krolewski: Phosphorylated interferon-alpha receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein. Embo Journal, 15, 1064-1074 (1996).
86. Gerhartz, C., B. Heesel, J. Sasse, U. Hemmann, C. Landgraf, J. SchneiderMergener, F. Horn, P. C. Heinrich & L. Graeve: Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130.1. Definition of a novel phosphotyrosine motif mediating STAT1 activation. Journal of Biological Chemistry, 271, 12991-12998 (1996).
87. Schindler, C., X. Y. Fu, T. Improta, R. Aebersold & J. E. Darnell: Proteins of Transcription Factor Isgf-3 - One Gene Encodes the 91-Kda and 84-Kda Isgf-3 Proteins That Are Activated by Interferon-Alpha. Proceedings of the National Academy of Sciences of the United States of America, 89, 7836-7839 (1992).
88. Shao, H., X. J. Xu, N. J. Jing & D. J. Tweardy: Structural requirements for design of peptidomimetics specifically targeting Stat3. Clinical Cancer Research, 9, 6239S-6239S (2003).
89. Naeger, L. K., J. McKinney, A. Salvekar & T. Hoey: Identification of a STAT4 binding site in the interleukin-12 receptor required for signaling. Journal of Biological Chemistry, 274, 1875-1878 (1999).
90. Schindler, U., P. G. Wu, M. Rothe, M. Brasseur & S. L. McKnight: Components of a Stat Recognition Code - Evidence for 2 Layers of Molecular Selectivity. Immunity, 2, 689-697 (1995).